NCT00547105View on ClinicalTrials.gov

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 25, 2007

Primary Completion Date

July 6, 2016

Study Completion Date

July 6, 2017

Conditions
Lung Cancer
Interventions
DRUG

Erlotinib

Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

RADIATION

SBRT

SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body

Trial Locations (2)

75390

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

80045

University of Colorado Cancer Center at UC Health Sciences Center, Aurora

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT00547105 - Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter